Metabolic syndrome abolishes glucagon-like peptide 1 receptor agonist stimulation of SERCA in coronary smooth muscle

Stacey L. Dineen, Mikaela L. McKenney, Lauren N. Bell, Allison M. Fullenkamp, Kyle A. Schultz, Mouhamad Alloosh, Naga Chalasani, Michael Sturek

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Metabolic syndrome (MetS) doubles the risk of adverse cardiovascular events. Glucagon-like peptide 1 (GLP-1) receptor agonists induce weight loss, increase insulin secretion, and improve glucose tolerance. Studies in healthy animals suggest cardioprotective properties of GLP-1 receptor agonists, perhaps partially mediated by improved sarco-endoplasmic reticulum Ca2+ ATPase (SERCA) activity. We examined the acute effect of GLP-1 receptor agonists on coronary smooth muscle cells (CSM) enzymatically isolated from lean, healthy Ossabaw miniature swine. Intracellular Ca2+ handling was interrogated with fura-2. The GLP-1 receptor agonist exenatide activated SERCA but did not alter other Ca2+ transporters. Further, we tested the hypothesis that chronic, in vivo treatment with GLP-1 receptor agonist AC3174 would attenuate coronary artery disease (CAD) in swine with MetS. MetS was induced in 20 swine by 6 months' feeding of a hypercaloric, atherogenic diet. Swine were then randomized (n = 10/group) into placebo or AC3174 treatment groups and continued the diet for an additional 6 months. AC3174 treatment attenuated weight gain, increased insulin secretion, and improved glucose tolerance. Intravascular ultrasound and histology showed no effect of AC3174 on CAD. MetS abolished SERCA activation by GLP-1 receptor agonists. We conclude that MetS confers vascular resistance to GLP-1 receptor agonists, partially through impaired cellular signaling steps involving SERCA.

Original languageEnglish (US)
Pages (from-to)3321-3327
Number of pages7
JournalDiabetes
Volume64
Issue number9
DOIs
StatePublished - Sep 1 2015

Fingerprint

Sarcoplasmic Reticulum Calcium-Transporting ATPases
Smooth Muscle
Swine
Coronary Artery Disease
Insulin
Atherogenic Diet
Miniature Swine
Glucose
Fura-2
Glucagon-Like Peptide-1 Receptor
Vascular Resistance
Weight Gain
Smooth Muscle Myocytes
Weight Loss
Histology
Therapeutics
Placebos
Diet
AC3174

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Metabolic syndrome abolishes glucagon-like peptide 1 receptor agonist stimulation of SERCA in coronary smooth muscle. / Dineen, Stacey L.; McKenney, Mikaela L.; Bell, Lauren N.; Fullenkamp, Allison M.; Schultz, Kyle A.; Alloosh, Mouhamad; Chalasani, Naga; Sturek, Michael.

In: Diabetes, Vol. 64, No. 9, 01.09.2015, p. 3321-3327.

Research output: Contribution to journalArticle

Dineen, Stacey L. ; McKenney, Mikaela L. ; Bell, Lauren N. ; Fullenkamp, Allison M. ; Schultz, Kyle A. ; Alloosh, Mouhamad ; Chalasani, Naga ; Sturek, Michael. / Metabolic syndrome abolishes glucagon-like peptide 1 receptor agonist stimulation of SERCA in coronary smooth muscle. In: Diabetes. 2015 ; Vol. 64, No. 9. pp. 3321-3327.
@article{0e8e21d3096a4db0a5fc5949c0b378a9,
title = "Metabolic syndrome abolishes glucagon-like peptide 1 receptor agonist stimulation of SERCA in coronary smooth muscle",
abstract = "Metabolic syndrome (MetS) doubles the risk of adverse cardiovascular events. Glucagon-like peptide 1 (GLP-1) receptor agonists induce weight loss, increase insulin secretion, and improve glucose tolerance. Studies in healthy animals suggest cardioprotective properties of GLP-1 receptor agonists, perhaps partially mediated by improved sarco-endoplasmic reticulum Ca2+ ATPase (SERCA) activity. We examined the acute effect of GLP-1 receptor agonists on coronary smooth muscle cells (CSM) enzymatically isolated from lean, healthy Ossabaw miniature swine. Intracellular Ca2+ handling was interrogated with fura-2. The GLP-1 receptor agonist exenatide activated SERCA but did not alter other Ca2+ transporters. Further, we tested the hypothesis that chronic, in vivo treatment with GLP-1 receptor agonist AC3174 would attenuate coronary artery disease (CAD) in swine with MetS. MetS was induced in 20 swine by 6 months' feeding of a hypercaloric, atherogenic diet. Swine were then randomized (n = 10/group) into placebo or AC3174 treatment groups and continued the diet for an additional 6 months. AC3174 treatment attenuated weight gain, increased insulin secretion, and improved glucose tolerance. Intravascular ultrasound and histology showed no effect of AC3174 on CAD. MetS abolished SERCA activation by GLP-1 receptor agonists. We conclude that MetS confers vascular resistance to GLP-1 receptor agonists, partially through impaired cellular signaling steps involving SERCA.",
author = "Dineen, {Stacey L.} and McKenney, {Mikaela L.} and Bell, {Lauren N.} and Fullenkamp, {Allison M.} and Schultz, {Kyle A.} and Mouhamad Alloosh and Naga Chalasani and Michael Sturek",
year = "2015",
month = "9",
day = "1",
doi = "10.2337/db14-1790",
language = "English (US)",
volume = "64",
pages = "3321--3327",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "9",

}

TY - JOUR

T1 - Metabolic syndrome abolishes glucagon-like peptide 1 receptor agonist stimulation of SERCA in coronary smooth muscle

AU - Dineen, Stacey L.

AU - McKenney, Mikaela L.

AU - Bell, Lauren N.

AU - Fullenkamp, Allison M.

AU - Schultz, Kyle A.

AU - Alloosh, Mouhamad

AU - Chalasani, Naga

AU - Sturek, Michael

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Metabolic syndrome (MetS) doubles the risk of adverse cardiovascular events. Glucagon-like peptide 1 (GLP-1) receptor agonists induce weight loss, increase insulin secretion, and improve glucose tolerance. Studies in healthy animals suggest cardioprotective properties of GLP-1 receptor agonists, perhaps partially mediated by improved sarco-endoplasmic reticulum Ca2+ ATPase (SERCA) activity. We examined the acute effect of GLP-1 receptor agonists on coronary smooth muscle cells (CSM) enzymatically isolated from lean, healthy Ossabaw miniature swine. Intracellular Ca2+ handling was interrogated with fura-2. The GLP-1 receptor agonist exenatide activated SERCA but did not alter other Ca2+ transporters. Further, we tested the hypothesis that chronic, in vivo treatment with GLP-1 receptor agonist AC3174 would attenuate coronary artery disease (CAD) in swine with MetS. MetS was induced in 20 swine by 6 months' feeding of a hypercaloric, atherogenic diet. Swine were then randomized (n = 10/group) into placebo or AC3174 treatment groups and continued the diet for an additional 6 months. AC3174 treatment attenuated weight gain, increased insulin secretion, and improved glucose tolerance. Intravascular ultrasound and histology showed no effect of AC3174 on CAD. MetS abolished SERCA activation by GLP-1 receptor agonists. We conclude that MetS confers vascular resistance to GLP-1 receptor agonists, partially through impaired cellular signaling steps involving SERCA.

AB - Metabolic syndrome (MetS) doubles the risk of adverse cardiovascular events. Glucagon-like peptide 1 (GLP-1) receptor agonists induce weight loss, increase insulin secretion, and improve glucose tolerance. Studies in healthy animals suggest cardioprotective properties of GLP-1 receptor agonists, perhaps partially mediated by improved sarco-endoplasmic reticulum Ca2+ ATPase (SERCA) activity. We examined the acute effect of GLP-1 receptor agonists on coronary smooth muscle cells (CSM) enzymatically isolated from lean, healthy Ossabaw miniature swine. Intracellular Ca2+ handling was interrogated with fura-2. The GLP-1 receptor agonist exenatide activated SERCA but did not alter other Ca2+ transporters. Further, we tested the hypothesis that chronic, in vivo treatment with GLP-1 receptor agonist AC3174 would attenuate coronary artery disease (CAD) in swine with MetS. MetS was induced in 20 swine by 6 months' feeding of a hypercaloric, atherogenic diet. Swine were then randomized (n = 10/group) into placebo or AC3174 treatment groups and continued the diet for an additional 6 months. AC3174 treatment attenuated weight gain, increased insulin secretion, and improved glucose tolerance. Intravascular ultrasound and histology showed no effect of AC3174 on CAD. MetS abolished SERCA activation by GLP-1 receptor agonists. We conclude that MetS confers vascular resistance to GLP-1 receptor agonists, partially through impaired cellular signaling steps involving SERCA.

UR - http://www.scopus.com/inward/record.url?scp=84962795005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962795005&partnerID=8YFLogxK

U2 - 10.2337/db14-1790

DO - 10.2337/db14-1790

M3 - Article

C2 - 25845661

AN - SCOPUS:84962795005

VL - 64

SP - 3321

EP - 3327

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 9

ER -